image description

Krishna Veeraraghavan


Krishna Veeraraghavan

New York +1-212-558-4000+1-212-558-4000 +1-212-558-3588+1-212-558-3588

Recognized in 2014 as “Dealmaker of the Week” by The American Lawyer and for his work on M&A mega-deals by The Legal 500 United States, Krishna Veeraraghavan is a partner and member of S&C’s Mergers and Acquisitions Group, focusing his practice on M&A, corporate governance and private equity matters. He has represented U.S. and non-U.S. companies, special committees, boards of directors and financial advisers in public company transactions, leveraged buyouts and private company sales of subsidiaries and divisions. Krishna has advised clients on a number of deals which have shaped and defined industries such as energy, technology, and healthcare and life sciences. He is an adjunct professor at Columbia Law School.


  • “Merger Market Perspective: Opportunities and Legal Issues in FinTech M&A,” FinTech Law Report (co-author) (November/December 2014)
  • “The Continuing Importance of Process in Entire Fairness Review: In re Nine Systems,” Deal Lawyers (co-author) (November/December 2014)
  • “Model Provision for Merger Agreement (Tender Offer),” Practical Law: The Journal (co-author) (October 2013)
  • “The Proxy Put and Fiduciary Duties: A Closer Look at Kallick v. SandRidge,” The M&A Lawyer (co-author) (July/August 2013)
  • “The Uncertain Relationship Between Fiduciary Waivers & the Implied Covenant of Good Faith in Delaware Alternative Entity Law,” The M&A Lawyer (co-author) (April 2013)
  • “Using Option Structures to Reduce Buyer Risk in Pharmaceutical M&A Deals,” Practical Law Company practice note (co-author) (April 2013)
  • “Qualitative Disclosure & Financial Projects: Overshadowed Lessons from In re,” Columbia Law School’s Blue Sky Blog (co-author) (March 2013)
  • “Confidentiality Agreements: Lessons from Delaware,” Bloomberg Law – Practitioner Contributions (co-author) (March 2013)
  • “Recent Delaware Developments: Three Cases with Surprising Outcomes that Reinforce Traditional Fiduciary Principles,” Columbia Law School’s Blue Sky Blog (co-author) (March 2013)
  • “What You Need to Know Before You Receive an Unsolicited Bid,” The M&A Lawyer (co-author) (February 2013)
  • “Memo to the Board of Directors: Preparing for 2013,” Bloomberg/BNA’s Corporate Accountability Report (co-author) (December 2012/January 2013)
  • “Preparing and Disclosing Financial Projections in Public M&A,” Practical Law: The Journal (co-author) (December 2012/January 2013)
  • “FCPA for Dealmakers: A Tutorial,” The Deal Pipeline (co-author) (August 2012)
  • “What You Need to Know About the FCPA Before You Do Your Next Deal,” The M&A Lawyer (co-author) (July/August 2012)

Rankings and Recognitions

  • The American Lawyer – Recognized as Dealmaker of the Week (2014)
  • Selected as one of National Asian Pacific American Bar Association’s (NAPABA) "Best Lawyers Under 40" (2014)
  • The Legal 500 United States – Recognized for M&A: Mega-Deals ($5BN+) (2014)
  • IFLR1000 – Recognized as a Leading Lawyer (2013, 2014, 2015)
  • New York Super Lawyers – Recognized as a Super Lawyer for Mergers & Acquisitions (2014)
  • Law360 – Recognized as a Rising Star for Mergers & Acquisitions (2014)
  • M&A Advisor – Named an M&A Advisor Award Finalist for "Legal Advisor of the Year" (2013)
  • Diversity & the Bar – Recognized as one of four Rising Stars by the Minority Corporate Counsel Association (MCCA) (March/April 2013)
  • New York Super Lawyers – Recognized as a Rising Star for Mergers & Acquisitions (2011, 2012, 2013, 2014)
  • M&A Advisor – Recognized as one of 40 top professionals who have reached a significant level of success in their careers under the age of 40, in the publication’s annual “40 Under 40” ranking (2012)

Speaking Engagements

  • Co-presenter, "The Art of Negotiation,” (October 2014)
  • Co-presenter, “M&A Non-Disclosure Agreements: Drafting and Key Issues that Can Affect the Course of a Deal,” Practising Law Institute webcast (June 2013)
  • Co-presenter, “Preparing and Disclosing Financial Projections in Public M&A,” Practising Law Institute’s Securities Law Practice Center (February 2013)
  • Co-presenter, “FCPA Due Diligence in Cross-Border Transactions,” Practising Law Institute’s “Hot Topic” briefing (December 2012)
  • Conference Co-Chairman, “Best Practices in Due Diligence: Addressing Due Diligence Challenges in a Rapidly Changing Global M&A Environment,” Executive Enterprise Institute (December 2012)

Professional Activities and Community Involvement

  • Columbia Law School – Adjunct Professor
  • American Bar Association – Committee on Mergers and Acquisitions
  • American India Foundation – Board of Trustees
  • Columbia Law School – Steering Committee of the Board of Visitors
  • Columbia Law School’s Blue Sky Blog – Advisory Board
  • Leadership Council on Legal Diversity (LCLD) – 2013 Fellow
  • South Asian Youth Action (SAYA!) – Board of Directors


  • in connection with various corporate matters
  • Amgen, the world’s largest biotechnology company, in its $315 million acquisition of KAI Pharmaceuticals
  • Anheuser-Busch InBev in its $20.1 billion acquisition of the remaining stake in Grupo Modelo that it did not already own; its $2.9 billion sale of Compañía Cervecera de Coahuila to Constellation Brands; its $1.85 billion sale of a 50% interest in Crown Imports to Constellation Brands; and the $2.7 billion sale of its entertainment parks business to an affiliate of Blackstone
  • AT&T in its $780 million acquisition of Atlantic Tele-Network’s domestic retail wireless business; its $950 million sale of AT&T Advertising Solutions and AT&T Interactive to an affiliate of Cerberus Capital Management; its $2.35 billion acquisition of certain wireless assets from Verizon Wireless; and its related $240 million sale of certain wireless assets to Verizon Wireless
  • Aurobindo Pharma USA in its acquisition of Natrol
  • BHP Billiton in its $15.1 billion acquisition of Petrohawk Energy
  • Cablevision in its $500 million acquisition of the Sundance Channel
  • Centerview Partners, as financial adviser to InterMune, Inc., in its $8.3 billion acquisition by Roche
  • Coleman Cable, Inc. in its $786 million acquisition by Southwire Company
  • Constellation Energy in the sale of its downstream natural gas unit to Macquarie Group
  • Cyberonics in its $3.3 billion pending merger with Sorin S.p.A.
  • Dynegy in its proposed acquisition by The Blackstone Group and Icahn Enterprises, respectively
  • Eastman Kodak in the $527 million sale of its digital imaging patent portfolio to a consortium organized by Intellectual Ventures and RPX Corporation and in the $2.55 billion sale of its health segment business to Onex Corporation
  • Harris in its $525 million acquisition of CapRock Communications
  • Senior management in connection with the $33 billion acquisition of HCA by a consortium of private equity funds
  • The Heyman family in its $3.2 billion sale of International Specialty Products (ISP) to Ashland
  • Highgate Hotels L.P. in its minority interest investment by Trilantic Capital Partners
  • Idenix Pharmaceuticals in its $3.85 billion acquisition by Merck
  • Impax Laboratories, Inc. in its $700 million pending acquisition of Tower Holdings, Inc. including operating subsidiaries CorePharma LLC, Amedra Pharmaceuticals LLC, and Lineage Therapeutics Inc. and its acquisition of two pharmaceutical products from Actavis, Inc.
  • IMS in its $5.2 billion sale to investment funds managed by TPG Capital and Canada Pension Plan Investment Board
  • Laboratory Corporation of America Holdings in its approximately $6.1 billion acquisition of Covance Inc.
  • Lion Capital and Bumble Bee Foods in connection with Bumble Bee’s $1.51 billion pending acquisition by Thai Union Frozen Products Public Company Limited
  • NBTY in its $4 billion acquisition by The Carlyle Group
  • The transactions committee of PepsiAmericas in PepsiAmericas’ $2 billion acquisition by PepsiCo
  • Perrigo Company in its approximately $8.6 billion acquisition of Elan Pharmaceutical
  • Pharmasset in its $11 billion acquisition by Gilead Sciences
  • Praxair in its $1.1 billion acquisition of NuCO2
  • Royal Philips in its $5.1 billion acquisition of Respironics and its $2.7 billion acquisition of The Genlyte Group
  • RR Donnelley & Sons Co. in its $620 million acquisition of Consolidated Graphics Inc.
  • UBS in the sale of its Canadian-based commodities energy business and global agricultural commodities business to J.P. Morgan
  • Whitehall in its $2.2 billion acquisition of Equity Inns